We previously described the clinical usefulness of a five biomarker panel (Millar et al, 2009b; ER, PR, HER2, CK 5/6 and EGFR) and have further defined luminal tumours by including Ki-67 and p53 status, the latter described in higher grade tumours, overexpressed more frequently within LB (Sorlie, 2004; Jacquemier et al, 2008; Hugh et al, 2009; Carey, 2010; Weigelt et al, 2010b) and as a predictor of endocrine resistance in some studies (Yamashita et al, 2006). This evidence concerns the gene MKI67 and neoplasm.